Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06769425 as recruiting, last updated 2025-06-24. Enrolment is 157 planned participants, an estimate. Interventions: HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib, HS-10502 + HS-20089, HS-10502 + Platinum + Bevacizumab, HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan, HS-10502 + Bevacizumab. Primary measures include Maximum tolerated dose (MTD) of HS-10502（Stage 1：Dose escalating stage）; Maximum applicable dose (MAD) of HS-10502（Stage 1：Dose escalating stage）. No results are posted in the registry; this does not exclude separate publications.
Shares HS-10502, PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Breast cancer (all types), Prostate cancer.
Shares PARP, Ovarian cancer, Breast cancer (all types), Prostate cancer.
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Ovarian cancer, Prostate cancer.
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/